Cantor Fitzgerald reiterates Rocket Lab stock rating, cites record revenue By Investing.com

Rocket Lab reported record Q3 2025 revenue of roughly $155 million, up 52.4% year-over-year, and maintains a contracted backlog of about $1.1 billion with management expecting ~57% to be recognized as revenue within 12 months. The company preserved operational momentum with 18 successful Electron launches in 2025 (100% success rate) and reaffirmed launch targets, while remaining unprofitable on a negative LTM EBITDA of $192.2 million but holding a healthy current ratio of 3.18; analysts including Cantor Fitzgerald (Overweight, $72 PT) and Needham (Buy, $63 PT) cited the strong backlog and execution ahead of near-term catalysts (SDA Tranche 3 decision in Q1 2026 and the first Neutron launch in Q2 2026).

Analysis

Market structure: Rocket Lab (RKLB) is a direct beneficiary of robust small-launch demand — $1.1bn backlog with ~57% expected to convert to revenue in the next 12 months implies near-term capacity tightness and pricing power versus boutique competitors. Suppliers of composite structures, avionics and smallsat integrators stand to gain; legacy incumbents (non‑public SpaceX aside) see pressure on share of the sub‑600kg market. Cross‑asset: a positive readthrough for small‑cap aero/defense ETFs (ARKX, ITA) and higher implied equity vol for RKLB; minimal direct FX/commodity impact but higher insurance/pricing for launch underwriters is probable.

Risk assessment: Key tail risks are launch failure (reputational + contract loss), missing the SDA Tranche‑3 award (decision Q1 2026), Neutron inaugural delay (target Q2 2026), and equity dilution if cash needs rise (negative EBITDA ~$192m LTM). Immediate (days): earnings/analyst revisions and JAXA mission outcomes; short (weeks–months): SDA award; long (quarters–years): path to sustained positive EBITDA and Neutron commercial cadence. Hidden dependencies include supplier throughput, insurance limits, and government contract timing that can shift revenue recognition windows.

Trade implications: Construct a disciplined overweight in RKLB sized 2–3% of equity risk with a hard stop-loss (18–25%) and profit targets at analyst bands ($63–$72) over 6–12 months; accumulate into weakness through Q1 2026 and trim into Neutron first flight in Q2 2026. Relative trade: go long RKLB vs short ARKX (equal notional) to isolate idiosyncratic launch upside. Options: buy a Jun‑2026 call spread (long ATM, short +30–50% strike) sized to 0.5–1% portfolio to capture catalyst upside; sell 3‑month OTM puts to collect premium if willing to own at a lower basis.

Contrarian angles: The market is underpricing operational execution risk and dilution risk—52% y/y revenue growth hides cash burn and negative EBITDA; consensus may under-appreciate a failed Neutron debut or an SDA loss that would compress multiple valuation scenarios. Historical parallels (early commercial launch firms) show binary outcomes: fast scale-up or severe retrenchment; be prepared to pivot within 30–90 days after any major negative catalyst.

Key Decisions for Investors

• Establish a 2–3% long equity position in RKLB now, scale in through Q1 2026 ahead of the Space Development Agency Tranche‑3 decision; use a stop-loss at 18% below entry and plan to take 50% off the position at $63 and the remainder at $72 within 6–12 months.
• Implement a relative-value pair: long RKLB and short ARKX (equal notional, net neutral sector beta) sized to 1–2% portfolio to capture idiosyncratic upside from launch cadence while hedging broader space sector risk; rebalance after SDA decision or Neutron flight.
• Buy a Jun‑2026 call spread (long ATM call, short call at ATM+30–50%) sized to 0.5–1% portfolio to play the Q1 SDA decision and Q2 Neutron inaugural; finance cost by selling 3‑month OTM puts ~10–15% below current price if willing to be assigned.
• If RKLB rallies >40% pre‑Neutron without new contract wins, trim exposure to 1% due to binary risk; conversely, if Neutron is delayed >3 months or SDA award is negative, reduce to zero and re‑evaluate on signs of structural cash‑flow improvement.